Celgene-Juno Therapeutics deal receives US antitrust clearance
MLex Summary: Celgene Corporation and Juno Therapeutics have announced that the waiting period under the US Hart-Scott-Rodino Act expired on Feb. 20, giving them clearance to proceed. According to a securities...To view the full article, register now.
Already a subscriber? Click here to view full article